These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1318682)

  • 21. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.
    Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human rhinovirus capsid dynamics is controlled by canyon flexibility.
    Reisdorph N; Thomas JJ; Katpally U; Chase E; Harris K; Siuzdak G; Smith TJ
    Virology; 2003 Sep; 314(1):34-44. PubMed ID: 14517058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas-phase electrophoretic mobility molecular analysis: Part I.
    Weiss VU; Subirats X; Pickl-Herk A; Bilek G; Winkler W; Kumar M; Allmaier G; Blaas D; Kenndler E
    Electrophoresis; 2012 Jul; 33(12):1833-41. PubMed ID: 22740471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.
    Rozhon E; Cox S; Buontempo P; O'Connell J; Slater W; De Martino J; Schwartz J; Miller G; Arnold E; Zhang A
    Antiviral Res; 1993 May; 21(1):15-35. PubMed ID: 8391247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.
    Rollinger JM; Schmidtke M
    Med Res Rev; 2011 Jan; 31(1):42-92. PubMed ID: 19714577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Separation and biospecific identification of subviral particles of human rhinovirus serotype 2 by capillary zone electrophoresis.
    Okun VM; Blaas D; Kenndler E
    Anal Chem; 1999 Oct; 71(20):4480-5. PubMed ID: 10546529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation.
    Edlmayr J; Niespodziana K; Popow-Kraupp T; Krzyzanek V; Focke-Tejkl M; Blaas D; Grote M; Valenta R
    Eur Respir J; 2011 Jan; 37(1):44-52. PubMed ID: 20530036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rhinoviruses.
    Stott EJ; Killington RA
    Annu Rev Microbiol; 1972; 26():503-24. PubMed ID: 4343002
    [No Abstract]   [Full Text] [Related]  

  • 30. Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.
    Andries K; Rombaut B; Dewindt B; Boeyé A
    J Virol; 1994 May; 68(5):3397-400. PubMed ID: 8151800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2.
    Hastings GZ; Speller SA; Francis MJ
    J Gen Virol; 1990 Dec; 71 ( Pt 12)():3055-9. PubMed ID: 1703215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based drug design of antirhinoviral compounds.
    Giranda VL
    Structure; 1994 Aug; 2(8):695-8. PubMed ID: 7994569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
    Patick AK; Brothers MA; Maldonado F; Binford S; Maldonado O; Fuhrman S; Petersen A; Smith GJ; Zalman LS; Burns-Naas LA; Tran JQ
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2267-75. PubMed ID: 15917520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human rhinovirus 3 at 3.0 A resolution.
    Zhao R; Pevear DC; Kremer MJ; Giranda VL; Kofron JA; Kuhn RJ; Rossmann MG
    Structure; 1996 Oct; 4(10):1205-20. PubMed ID: 8939746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Labeling of capsid proteins and genomic RNA of human rhinovirus with two different fluorescent dyes for selective detection by capillary electrophoresis.
    Kremser L; Petsch M; Blaas D; Kenndler E
    Anal Chem; 2004 Dec; 76(24):7360-5. PubMed ID: 15595880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
    Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW; Matthews DA; Patick AK
    Antimicrob Agents Chemother; 2005 Feb; 49(2):619-26. PubMed ID: 15673742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses.
    Lacroix C; Laconi S; Angius F; Coluccia A; Silvestri R; Pompei R; Neyts J; Leyssen P
    Virol J; 2015 Jul; 12():106. PubMed ID: 26169596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
    Watson KG; Brown RN; Cameron R; Chalmers DK; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell DB; Reece PA; Ryan J; Stanislawski PC; Tucker SP; Wu WY; Barnard DL; Sidwell RW
    J Med Chem; 2003 Jul; 46(15):3181-4. PubMed ID: 12852746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of the antiviral compound MDL 20,610.
    Kenny MT; Torney HL; Dulworth JK
    Antiviral Res; 1988 Jul; 9(4):249-61. PubMed ID: 2849377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human rhinovirus 14 complexed with antiviral compound R 61837.
    Chapman MS; Minor I; Rossmann MG; Diana GD; Andries K
    J Mol Biol; 1991 Feb; 217(3):455-63. PubMed ID: 1847215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.